Sterile Injectable Contract Manufacturing Market To Reach $31.9 Billion By 2030

Sterile Injectable Contract Manufacturing Market Growth & Trends

The global sterile injectable contract manufacturing market size is expected to reach USD 31.9 billion by 2030, registering a CAGR of 12.28% from 2025 to 2030, according to a new report by Grand View Research, Inc. Increasing pipeline and approvals of injectables, growing demand for biologics and biosimilars, rise in investment in research & development activities for the development of novel therapeutics, and increasing demand for cell & gene therapies are the key factors driving the growth of sterile injectable contract manufacturing industry. The market for sterile injectable contract manufacturing is fragmented, with several players having similar technological and processing capabilities.

Contract Manufacturing Organizations (CMOs) with unique capabilities, such as the management of high-potency drugs, are anticipated to dominate the industry. In Europe and the U.S., there are various sterile injectable CMOs with EU GMP and U.S. FDA-approved facilities. Moreover, developing economies such as India and China are anticipated to witness lucrative growth across the forecast period. This is attributable to the increasing demand for injectable sourcing services across these countries. India has over 20 CMOs with EU GMP/U.S. FDA injectable certifications. The Indian sterile injectable contract manufacturing industry is rapidly expanding due to rising demand for outsourcing services from the pharmaceutical giants to emerging markets for cost-effectiveness. Most Indian injectable CMOs have been catering to local demand, but the transition has been evident over the past few years.

The COVID-19 pandemic positively impacted the sterile injectable contract manufacturing industry. This was because of the huge surge in demand for COVID-19 vaccines from 2020 to 2021, as these vaccines are a major part of the injectables industry. In addition, major players in the market are adopting inorganic strategic initiatives such as mergers, acquisitions, and partnerships to enhance their market positions. Furthermore, for the past few years, several companies have focused on penetrating the injectable contract manufacturing industry. For instance, Bridgewest Group, a global private investment firm, announced the launch of a new contract development and manufacturing organization (CDMO) facility focused on sterile injectable drug products.

 Request a free sample copy or view report summary: Sterile Injectable Contract Manufacturing Market Report

Sterile Injectable Contract Manufacturing Market Report Highlights

• Based on molecule type, the large molecule segment led the market with the largest revenue share of 67.07% in 2024. The growth of the segment is mainly due to rising investments by contract manufacturers in developing large molecule-based therapeutics, an expanding pipeline of biologics injectables, and a notable increase in U.S. FDA approvals for biosimilars.

• Based on therapeutic application, the cancer segment led the market with the largest revenue share of 28.17% in 2024. The increasing number of cancer cases, rising R&D investments, and growing requirements for oncology drugs & biologics are some of the factors driving the segment growth.

• Based on route of administration, the intravenous (IV) segment led the market with the largest revenue share of 30.35% in 2024. Several healthcare systems are shifting toward personalized medicine, which is boosting the demand for tailored intravenous therapies.

• Based on end use, the pharmaceutical companies segment led the market with the largest revenue share of 43.48% in 2024. Pharmaceutical companies are increasingly outsourcing their drug development and manufacturing operations to Contract Manufacturing Organizations (CMOs) to focus on their core competencies, such as R&D.

• North America sterile injectable contract manufacturing market dominated with the revenue share of 42.86% in 2024. The growth in the region is attributed to the factors such as to the region’s advanced healthcare infrastructure, increasing R&D investment, technological developments, and the presence of major players. 

Sterile Injectable Contract Manufacturing Market Segmentation

Grand View Research has segmented global sterile injectable contract manufacturing market report based on molecule type, therapeutic application, route of administration, end-use, and region:

Sterile Injectable Contract Manufacturing Molecule Type Outlook (Revenue, USD Million, 2018 - 2030)

• Small Molecule

• Large Molecule

Sterile Injectable Contract Manufacturing Therapeutic Application Outlook (Revenue, USD Million, 2018 - 2030)

• Cancer

• Diabetes

• Cardiovascular Diseases

• Central Nervous Systems Diseases

• Infectious Disorders

• Musculoskeletal

• Anti-viral

• Others

Sterile Injectable Contract Manufacturing Route Of Administration Outlook (Revenue, USD Million, 2018 - 2030)

• Subcutaneous (SC)

• Intravenous (IV)

• Intramuscular (IM)

• Others

Sterile Injectable Contract Manufacturing End-use Outlook (Revenue, USD Million, 2018 - 2030)

• Pharmaceutical Companies

• Biopharmaceutical Companies

• Others

Sterile Injectable Contract Manufacturing Regional Outlook (Revenue, USD Million, 2018 - 2030)

• North America

  • U.S.

  • Canada

  • Mexico

• Europe

  • UK

  • Germany

  • France

  • Italy

  • Spain

  • Denmark

  • Sweden

  • Norway

• Asia Pacific

  • Japan

  • China

  • India

  • Australia

  • South Korea

  • Thailand

• Latin America

  • Brazil

  • Argentina

• Middle East & Africa

  • South Africa

  • Saudi Arabia

  • UAE

  • Kuwait

List of Key Players in the Sterile Injectable Contract Manufacturing Market

• Baxter

• Catalent, Inc.

• Vetter Pharma

• Recipharm AB

• Aenova Group

• Fresenius Kabi AG

• Unither Pharmaceuticals

• FAMAR Health Care Services

• Cipla Inc.

• NextPharma Technologies